176750.KQ DuChemBIO Co.,Ltd.
- Market cap
- KRW 173B
- P/E
- 26.6x
- P/B
- 3.35x
- ROE
- 8.1%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 176750.KQ undervalued?
Graham number176750.KQ trades 99.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DuChemBIO Co.,Ltd. fundamental analysis
4 of 22 checks passedROE 0/2
Low return on equity (8.1%), below 10%.
ROA 0/1
Return on assets (5.4%) is below the industry median (5.4%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-18.9%) is below the industry median (88.7%).
Revenue Growth 1/2
Revenue grew 6.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 4.7x against interest expense, below 5x.
PE vs Market 0/1
PE (26.6x) is above the market median (11.3x).
PE vs Industry 0/1
PE (26.6x) is above the industry median (19.0x).
PBV 0/1
Price to book (3.4x) is above the industry median (1.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 89.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
DuChemBIO Co.,Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DuChemBIO Co.,Ltd.
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of b…
Full company profileDuChemBIO Co.,Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DuChemBIO Co.,Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 32.4B | 34.7B | 35.6B | 38.6B | 41.8B |
| Gross Profit | 8.70B | 11.8B | 12.2B | 14.2B | 14.8B |
| Operating Income | 1.56B | 5.26B | 5.08B | 7.44B | 6.37B |
| EBITDA | 6.11B | 11.2B | 12.2B | 14.6B | 16.4B |
| Net Income | -2.60B | 4.00B | 7.99B | 6.48B | 4.15B |
| EPS | -97 | 150 | 282 | 229 | 146 |
| Balance Sheet | |||||
| Total Assets | 51.4B | 49.3B | 65.2B | 77.7B | 77.6B |
| Total Liabilities | 33.8B | 27.5B | 22.2B | 28.4B | 26.0B |
| Shareholders' Equity | 17.6B | 21.8B | 43.0B | 49.2B | 51.6B |
| Cash & Short-term Investments | 2.59B | 1.97B | 10.7B | 15.4B | 19.0B |
| Cash Flow | |||||
| Operating Cash Flow | 8.24B | 8.44B | 7.03B | 9.94B | 15.4B |
| Capital Expenditure | 731M | 1.30B | 1.87B | 878M | 405M |
| Free Cash Flow | 7.51B | 7.14B | 5.16B | 9.06B | 15.0B |
| Ratios | |||||
| ROE | -14.8% | 18.4% | 18.6% | 13.2% | 8.1% |
| ROA | -5.1% | 8.1% | 12.3% | 8.3% | 5.4% |
| Net Profit Margin | -8.0% | 11.5% | 22.5% | 16.8% | 9.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
DuChemBIO Co.,Ltd. dividends
DuChemBIO Co.,Ltd. has not paid dividends in the last 4 fiscal years.
Who owns DuChemBIO Co.,Ltd.
- Insiders 60.80%
- Institutions 0.54%
- Public & others 38.66%
- Shares outstanding 28.4M
- Free float 11.1M
DuChemBIO Co.,Ltd. company profile
- Company name
- DuChemBIO Co.,Ltd.
- Ticker
- 176750.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 146
- Fiscal year end
- December
- Address
- 81, Wausan-ro, Seoul, South Korea, 04041
- Phone
- 82 2 332 4868
- Website
- duchembio.com
About DuChemBIO Co.,Ltd.
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
DuChemBIO Co.,Ltd. management
1- Sang-Woo KimChief Executive Officer